Shimoyama Naohito, Shimoyama Megumi
Department of Anesthesiology, Jikei Medical University, Tokyo 105-8471.
Masui. 2013 Jul;62(7):822-8.
The treatment of chronic pain, whether of cancer or noncancer origin, frequently involves the use of opioids. Delay in GI transit and constipation are the most common and often disabling side effects of opioid analgesics. Many treatments involving laxatives and prokinetic drugs have been explored to circumvent opioid-induced bowel dysfunction, but the outcome has in general been unsatisfactory. Specific antagonism of peripheral opioid receptors offers a more rational approach to the management of the adverse actions of opioid analgesics in the gut. This goal is currently addressed by the use of opioid receptor antagonists with limited absorption such as oral naloxone and by the development of peripheral opioid receptor antagonists such as methylnaltrexone and alvimopan. These drugs hold considerable promise in preventing constipation due to treatments with opioids, whereas the analgesic action of opioids remains unabated.
慢性疼痛的治疗,无论其源于癌症还是非癌症,通常都涉及阿片类药物的使用。胃肠道转运延迟和便秘是阿片类镇痛药最常见且往往会导致功能障碍的副作用。人们探索了许多使用泻药和促动力药物的治疗方法来规避阿片类药物引起的肠功能障碍,但总体结果并不理想。外周阿片受体的特异性拮抗作用为处理阿片类镇痛药在肠道中的不良反应提供了一种更合理的方法。目前,通过使用吸收有限的阿片受体拮抗剂(如口服纳洛酮)以及开发外周阿片受体拮抗剂(如甲基纳曲酮和阿维莫潘)来实现这一目标。这些药物在预防阿片类药物治疗引起的便秘方面具有很大的前景,而阿片类药物的镇痛作用仍未减弱。